A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis
A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Inclusion Criteria:
Exclusion Criteria:
global-roche-genentech-trials@gene.com888-662-6728 (U.S. and Canada)
Dothan, Alabama 36305, United States
Newport Beach, California 92663, United States
Tampa, Florida 33612, United States
Glenview, Illinois 60026, United States
Wichita, Kansas 67226, United States
Louisville, Kentucky 40218, United States
Shreveport, Louisiana 71105, United States
Lebanon, New Hampshire 03756, United States
The Bronx, New York 10468, United States
Charlotte, North Carolina 28207, United States
Ciudad Autonoma Bs As, C1280AEB, Argentina
Sofia Town, Sofia 1202, Bulgaria
Shanghai, 200092, China
Ostrava - Poruba, 708 52, Czechia
Gachibowli, Telangana 500032, India
Bologna, Emilia-Romagna 40138, Italy
Monza MI, Lombardy 20900, Italy
Miguel Hidalgo, Mexico CITY (federal District) 01120, Mexico
?ód?, 93-357, Poland
Bia?ystok, 15-322, Poland
Grudzadz, 86-300, Poland
I?awa, 14-200, Poland
Wroc?aw, 52-210, Poland
Santa Maria da Feira, 4520-211, Portugal
Majadahonda, Madrid 28222, Spain
Chiang Mai, 50200, Thailand
Ubonratchathani, 34000, Thailand